Technology
Pipeline
Next-generation In Vitro and In Vivo oncology products that address the demand for radiopharmaceuticals in cancer diagnosis and targeted cancer therapy. Our understanding of the GPCR-VPAC1 molecular receptors and its mechanisms of action has led us to develop a novel diagnostic and theranostic product pipeline for a variety of cancer indications.
NV-VPAC1
provides binary endpoints for the in vitro and in vivo diagnosis and subsequent treatment of numerous cancer indications
Multiple Diagnostic and Therapeutic Indications
Independent evaluation of VPAC1 receptor overexpression in human pathological samples1,2,2
Tumor Type VPAC1 Receptor Expression % by Cancer
Breast carcinoma 68/68 (100%)
Prostate carcinoma 37/37 (100%)
Meningioma (brain) 27/27 (100%)
Urinary Bladder carcinoma 4/4 (100%)
Endometrial carcinoma 12/12 (100%)
Paraganglioma 18/18 (100%)
Colorectal carcinoma 25/26 (96%)
Pheochromocytoma 18/25 (72%)
Leiomyoma 10/15 (66%)
Pancreatic carcinoma 26/40 (65%)
Lung carcinoma 23/40 (58%)
Non-Hodgkin's lymphoma 11/19 (58%)
Gastric carcinoma 14/26 (54%)
Liver carcinoma 29/59 (49%)
